Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

Circulation. 2002 Mar 12;105(10):1240-6. doi: 10.1161/hc1002.105225.

Abstract

Background: Peroxisome proliferator-activated receptors (PPARs) are transcription factors of the nuclear receptor superfamily. It has been reported that the thiazolidinediones, which are antidiabetic agents and high-affinity ligands for PPARgamma, regulate growth of vascular cells. In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice.

Methods and results: Treatment of cultured cardiac myocytes with PPARgamma ligands such as troglitazone, pioglitazone, and rosiglitazone inhibited Ang II-induced upregulation of skeletal alpha-actin and atrial natriuretic peptide genes and an increase in cell surface area. Treatment of mice with a PPARgamma ligand, pioglitazone, inhibited pressure overload-induced increases in the heart weight-to-body weight ratio, wall thickness, and myocyte diameter in wild-type mice and an increase in the heart weight-to-body weight ratio in heterozygous PPARgamma-deficient mice. In contrast, pressure overload-induced increases in the heart weight-to-body weight ratio and wall thickness were more prominent in heterozygous PPARgamma-deficient mice than in wild-type mice.

Conclusions: These results suggest that the PPARgamma-dependent pathway is critically involved in the inhibition of cardiac hypertrophy.

MeSH terms

  • Actins / genetics
  • Actins / metabolism
  • Angiotensin II / pharmacology
  • Animals
  • Atrial Natriuretic Factor / genetics
  • Atrial Natriuretic Factor / metabolism
  • Body Weight / drug effects
  • Cardiomegaly / metabolism
  • Cardiomegaly / pathology
  • Cardiomegaly / prevention & control*
  • Cell Size / drug effects
  • Cells, Cultured
  • Chromans / pharmacology
  • Disease Models, Animal
  • Gene Expression / drug effects
  • Heart / drug effects
  • Heterozygote
  • Hypoglycemic Agents / pharmacology
  • Ligands
  • Mice
  • Mice, Knockout
  • Myocardium / cytology
  • Myocardium / metabolism
  • Myocardium / pathology
  • Organ Size / drug effects
  • Pioglitazone
  • Rats
  • Rats, Wistar
  • Receptors, Cytoplasmic and Nuclear / deficiency
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Rosiglitazone
  • Thiazoles / pharmacology
  • Thiazolidinediones*
  • Transcription Factors / deficiency
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Troglitazone

Substances

  • Actins
  • Chromans
  • Hypoglycemic Agents
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • Rosiglitazone
  • Angiotensin II
  • Atrial Natriuretic Factor
  • Troglitazone
  • Pioglitazone